- Home
- BXC vs CVAC Comparison
BXC vs CVAC Comparison
Compare BXC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXC
- CVAC
- Stock Information
- Founded
- BXC 2004
- CVAC 2000
- Country
- BXC United States
- CVAC Germany
- Employees
- BXC N/A
- CVAC N/A
- Industry
- BXC Wholesale Distributors
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- BXC Consumer Discretionary
- CVAC Health Care
- Exchange
- BXC Nasdaq
- CVAC Nasdaq
- Market Cap
- BXC 869.2M
- CVAC 924.3M
- IPO Year
- BXC 2004
- CVAC 2020
- Fundamental
- Price
- BXC $110.28
- CVAC $4.14
- Analyst Decision
- BXC Strong Buy
- CVAC Hold
- Analyst Count
- BXC 3
- CVAC 3
- Target Price
- BXC $135.67
- CVAC $10.00
- AVG Volume (30 Days)
- BXC 57.8K
- CVAC 1.2M
- Earning Date
- BXC 02-18-2025
- CVAC 11-12-2024
- Dividend Yield
- BXC N/A
- CVAC N/A
- EPS Growth
- BXC N/A
- CVAC N/A
- EPS
- BXC 3.41
- CVAC N/A
- Revenue
- BXC $2,954,424,000.00
- CVAC $70,565,734.00
- Revenue This Year
- BXC N/A
- CVAC $742.57
- Revenue Next Year
- BXC $4.41
- CVAC N/A
- P/E Ratio
- BXC $31.32
- CVAC N/A
- Revenue Growth
- BXC N/A
- CVAC 75.11
- 52 Week Low
- BXC $87.67
- CVAC $2.22
- 52 Week High
- BXC $134.79
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- BXC 54.48
- CVAC 62.80
- Support Level
- BXC $105.68
- CVAC $3.89
- Resistance Level
- BXC $109.36
- CVAC $4.32
- Average True Range (ATR)
- BXC 3.97
- CVAC 0.34
- MACD
- BXC 1.55
- CVAC 0.01
- Stochastic Oscillator
- BXC 93.77
- CVAC 56.12
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.